-
Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China
•
Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the Phase III ENHANCE-CHINA study (NCT05743075) for its drug Ohtuvayre (ensifentrine). This Phase III trial is a randomized, double-blind, placebo-controlled investigation assessing the efficacy and safety of Ohtuvayre over a 24-week period in adult patients diagnosed…
-
Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics
•
Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore arbitration court in a dispute with Canada’s Antibe Therapeutics (OTCMKTS: ATBPF). The arbitration centered on a February 2021 agreement where Nuance acquired development and commercial rights for Antibe’s otenaproxesul (ATB-346), an innovative pain relief drug…
